Breast Cancer

I have been diagnosed with breast cancer for the third time, and I find it interesting how the places where I seek support have changed over time.

Clinical trials give patients with metastatic breast cancer access to new treatments, all while being closely monitored and moving the landscape forward.

Trodelvy led to fewer side effects that required dose reductions or stopping treatment vs chemo among previously untreated triple-negative breast cancer.

At the 2025 SABCS, researchers presented findings with the potential to meaningfully affect breast cancer treatment and patient care.

Enhertu wins breakthrough therapy designation in some patents with HER2+ early breast cancer who have residual disease following neoadjuvant treatment.

Despite its vital function in many patients’ cancer journeys, palliative care is still the subject of several persistent myths and misconceptions.

Integrative oncology combines standard treatment with evidence-based complementary therapies to manage symptoms and empower patients.

DESTINY-Breast05 analyses show post neoadjuvant Enhertu improves invasive disease free survival compared with Kadcyla in patients with residual early stage breast cancer.

Losing an online friend to cancer reminded me that grief is real even across screens and that survivor guilt and gratitude can coexist in the same moment.

This patient guide explains triple-positive breast cancer, including treatment options, side effects and more to support informed conversations.

When I was diagnosed with breast cancer, I accepted there would be things I couldn’t completely control.

Dr. Katherine Crew discusses how new HER2-directed therapies are improving survival in metastatic breast cancer.

The treatment of advanced HR+ breast cancer care is evolving, with targeted therapies and clinical trial progress offering a better quality of life.

Dispelling myths and misconceptions and shedding light on disparities in hospice care.

Treatment with the combination of NGC-Cap may increase the cancer-killing power of treatment without adding significant safety concerns.

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

I usually write about my daughter’s cancer, but my friend’s stage 4 breast cancer journey showed me the limits of strength and the need for help.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Hormone therapy after breast cancer did not increase risk in BRCA1/2 carriers; estrogen alone was linked to lower risk.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.